A significantly greater proportion of patients treated with upadacitinib 15mg and 30mg achieved clinical remission at week 52 compared with those receiving placebo.
Researchers analyzed the presence and effect of mucosal biofilms in patients with irritable bowel syndrome and ulcerative colitis.
Investigators compared rates of histologic remission and disease activity in patients with UC treated with vedolizumab vs adalimumab.
Investigators evaluated the safety and efficacy of adalimumab in pediatric patients with moderate to severe ulcerative colitis.
Researchers aimed to evaluate how bowel urgency and abdominal pain may improve with upadacitinib treatment, as indicted by health related quality of life outcomes.
Researchers analyzed the safety and efficacy of filgotinib in patients with moderately to severely active ulcerative colitis.
Researchers compared the clinical effectiveness and safety profiles of vedolizumab and anti-TNFα agents in biologic-naïve adult patients with ulcerative colitis and Crohn disease.
Positive topline results were announced from the phase 3 True North trial evaluating the efficacy of ozanimod as an induction and maintenance therapy for adults with moderate to severe ulcerative colitis.
Researchers analyzed malignancy events and their relationship to tofacitinib treatment levels in patients with ulcerative colitis.
Reviewers addressed potential reasons for the shortcomings of newer therapies and proposed solutions to increase treatment efficacy in ulcerative colitis.
Investigators conducted a randomized controlled trial to assess the use of fecal microbiota transplants in children with ulcerative colitis.
Investigators examined the safety and efficacy of tofacitinib re-treatment in patients with ulcerative colitis who underwent treatment interruption.
Researchers compared outcomes and remission rates among patients with ulcerative colitis who continue or discontinue treatment with infliximab.
The FDA has approved Zeposia® (ozanimod) for moderately to severely active ulcerative colitis in adults.
Researchers analyzed the rates of achieving corticosteroid-free remission in patients with ulcerative colitis receiving maintenance treatment with ozanimod vs placebo.
Researchers aimed to determine the safety and efficacy of tofacitinib in maintaining remission from ulcerative colitis over long-term follow up.
Researchers studied the interactions between diet, gut microbiota, and their functional ability to induce intestinal inflammation.
Researchers aimed to examine the association of anti-TNF with reduced mortality relative to prolonged corticosteroid use in a cohort of veterans with IBD.
In patients with IBD, management of immunosuppressive regimens, as well as safety and efficacy of vaccines, has raised many questions during the COVID-19 pandemic.
Researchers aimed to identify predictors and outcomes of ustekinumab dose intensification in 108 patients with ulcerative colitis.